LAUSANNE, Switzerland--(BUSINESS WIRE)--Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced publication of data from a phase I study demonstrating that the antisense oligonucleotide GS-101 (eye drops) is safe, with no signs of intolerability following administration to healthy volunteers. GS-101 is an antisense oligonucleotide that acts by blocking the production of insulin receptor substrate 1 (IRS-1), a protein required for the formation and growth of new blood vessels. The data were published in the August 2009 issue of the British Journal of Clinical Pharmacology (Vol. 68 (2) pp169-173) by researchers led by Dr. Hermann Kain, University Hospital Basel, Basle, Switzerland.
